

Japan's Marubeni buys Sumitomo's Asia pharma biz for ¥45 B

07 April 2025 | News

Marubeni will establish and strengthen a new platform



Japan-based Marubeni Corporation has concluded a Share Purchase Agreement with Sumitomo Pharma Co. to acquire shares in a newly established company that will take over Sumitomo Pharma's pharmaceutical sales business in Asia through a simplified absorption. Marubeni will acquire 60% of the issued shares of the new company for approximately 45 billion yen (¥).

The pharmaceutical market in Asia, where the new company is operating, is expected to continue to grow at a high rate in the long term due to population growth, ageing, and economic development. Marubeni will take over the pharmaceutical supply system, track record, and trust that Sumitomo Pharma has built up over the years and will contribute to local communities by improving the access to medicines in pharmaceutical areas other than drug discovery.

Marubeni has positioned its pharmaceutical-related business as one of the next-generation businesses in demand in countries around the world and has built a pharmaceutical sales business that handles more than 10,000 products, mainly in China, the Middle East, and Africa. Going forward, Marubeni will position the new company as its pharmaceutical strategic platform and will work to expand its products and the target regions in order to deliver needed products to patients around the world. This will enable Marubeni to grow its pharmaceutical-related business, with sales anticipated to reach more than 100 billion yen by FY2029.

In its Mid-Term Management Strategy (GC2027), Marubeni is focusing on Strategic Platform Investments. In this investment, Marubeni will establish and strengthen a new platform based on the knowledge and track record it has built up in the pharmaceutical sales business, thereby meeting the needs of various patients and creating high added value in the growing pharmaceutical market.